All Wise Information.Com
Clear Information To Make You Wiser.
Schizophrenia Information
FDA warns schizophrenia drugs pose fatal risk to some seniors (KWWL Iowa) WASHINGTON (AP) - The government is warning doctors that prescribing a certain group of psychiatric drugs to seniors suffering from dementia can increase their risk of death. ACADIA Pharmaceuticals Announces Results from ACP-104 Phase IIb Schizophrenia Trial (Business Wire via Yahoo! Finance) SAN DIEGO----ACADIA Pharmaceuticals Inc. today announced results from its Phase IIb trial with ACP-104 for the treatment of schizophrenia. The study did not meet its primary endpoint of antipsychotic efficacy or any of the secondary endpoints. ACADIA Pharmaceuticals Announces Results from ACP-104 Phase IIb Schizophrenia Trial (Centre Daily Times) ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD) today announced results from its Phase IIb trial with ACP-104 for the treatment of schizophrenia. The study did not meet its primary endpoint of antipsychotic efficacy or any of the secondary endpoints. Neither dose of ACP-104 demonstrated improved efficacy as compared to placebo. The most common adverse events in the treatment arms relative to placebo ... Schizophrenia drug by Acadia will be scrapped (San Diego Union-Tribune) Acadia Pharmaceuticals shares plummeted more than 40 percent yesterday after the San Diego company announced that its experimental schizophrenia drug failed in a midstage clinical trial. (AFX UK Focus) 2008-06-16 13:07 Acadia Pharma: ACP-104 Phase IIb schizophrenia trail missed primary endpoint (Interactive Investor) BOSTON (Thomson Financial) - Acadia Pharmaceuticals Inc. Monday said its Phase IIb study of ACP-104 for the treatment of schizophrenia did not meet its primary endpoint of antipsychotic efficacy or any of the secondary endpoints. Acadia schizophrenia drug fails mid-stage trial (AP via Yahoo! Finance) Biotechnology company Acadia Pharmaceuticals Inc. said Monday a midstage study showed its experimental drug was no better than placebo in treating schizophrenia. Schizophrenia drugs pose fatal risk to seniors: FDA (Deccan Herald) US health regulators warned doctors that prescribing a certain group of psychiatric drugs to seniors suffering from dementia can increase their risk of death. UT Tyler Assistant Professor Conducts Schizophrenia Research (Tyler Morning Telegraph) Dr. Dennis Combs, assistant professor of psychology at The University of Texas at Tyler, is conducting research to develop a new intervention in the treatment of schizophrenia, Dr. Arlene Horne, associate vice president for research and federal relations, announced. Ahead of the Bell: Acadia Pharmaceuticals (AP via Yahoo! Finance) Analysts turned their attention to Acadia Pharmaceuticals Inc.'s future and its drug candidate pimavanserin Tuesday, a day after the company reported the failure of another schizophrenia drug. FDA warns doctors that schizophrenia drugs pose fatal risk to seniors with dementia (Canadian Business) Matthew Perrone June 16, 2008 - 5:42 p.m. WASHINGTON (AP) - The Food and Drug Administration warned doctors Monday that prescribing a certain group of psychiatric drugs to seniors suffering from dementia can increase their risk of death. |
|
All Shopping Information All Business Information All Automotives Information All Banking Information All Electronics Information All Financial Information All Entertainment Information All Health Information All Home Improvement Information All Home Theaters Information All Insurance Information All Legal Services Information All Money Information All Internet Information All Property Information All Vacations information All Travel Information All Economy Information All Investment information All Technology Information |
Wise Information Categories
All information and links are auto loaded daily to give you updated wise information
All Wise Information Wise Information News Archives Information Posts Search Partner Directories Contact Us Privacy Statement Site Map
All Wise Information.Com
© Copyright All Wise Information®